CM
AKBA icon

Crestline Management’s Akebia Therapeutics AKBA Stock Holding History

Crestline Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-35,098
Closed -$504K – 124
2017
Q2 		$504K Buy
+35,098
New +$445K 0.07% 112

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Crestline Management's AKBA Position: Q3 2017 in Review

Crestline Management sold out of Akebia Therapeutics (AKBA) in Q3 2017, closing a stake of 35,098 shares — an estimated $504K sold.

Crestline Management first reported a position in AKBA in Q2 2017 and held it in 1 quarter. The position peaked at $504K in Q2 2017. 119 funds tracked by Wall St. Rank hold AKBA as of Q3 2017.

  • Crestline Management reported no remaining Akebia Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Crestline Management sold 35,098 Akebia Therapeutics shares in Q3 2017, an estimated $504K.
  • Crestline Management first reported a position in Akebia Therapeutics in Q2 2017 and held it in 1 quarter.
  • Crestline Management's Akebia Therapeutics position peaked at $504K in Q2 2017.
  • 119 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.